licensing agreement

Merck & Co. Licenses Investigational Cancer Drug from LaNova

US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.

Dr. Reddy's Enters into a Licensing Agreement with Gilead for Remdesivir

Pioneer and Origin Agritech in Seeds Deal

Valent BioSciences, Lidochem in Technology Pact

Starpharma in Drug Delivery Pact with AstraZeneca

Lubrizol Takes Daelim License for US Polyisobutylenes Plant

DuPont Technology for Cellulose Ethanol in China Biofuels